Goswami et al., also demonstrated in a murine bladder model that the combination of EZH2 inhibition and anti-CTLA-4 was able to mediate an even stronger inhibition of tumor growth than respective monotherapies [185,191]. Here, CTLA4 is linked to neoplasm.